Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter studyFumihiko Urabe, Takahiro Kimura, Takafumi Yanagisawa et al.|Japanese Journal of Clinical Oncology|2024Cited by 22
Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter studyTakafumi Yanagisawa, Takahiro Kimura, Wataru Fukuokaya et al.|The Prostate|2024Cited by 19
Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: Real-world data from a multicenter studyFumihiko Urabe, Takahiro Kimura, Kojiro Tashiro et al.|Urologic Oncology Seminars and Original Investigations|2025Cited by 11
PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone‐Sensitive Prostate Cancer (mHSPC) in Real‐World Analyses?Tatsuya Shimomura, Naoki Otsuka, Fumihiko Urabe et al.|The Prostate|2025Cited by 4
Evaluating CRPC Definition: Comparing Upfront ARSI and Conventional Hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Real World Propensity Score Matched CohortTatsuya Shimomura, Katsuki Muramoto, Takafumi Yanagisawa et al.|The Prostate|2025Cited by 3